fromSilicon Valley Journals
3 months agoA biotech company which developing therapies for orphan diseases raises $115M in funding
Glycomine's progress towards delivering the first disease-modifying therapy for a rare genetic disorder was bolstered by a $115 million Series C funding round.
Startup companies